Alkane Resources Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 24K
- Market Cap
- -
- Introduction
Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Mainline, Regional, and Horizon. The Mainline segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, Costa Rica and Belize. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Horizon segment encompasses the capacity sold to Alaska under a CPA. The company was founded in 1985 and is headquartered in Seattle, WA.
ALNEO Trial Demonstrates Promising Perioperative Alectinib Activity in Stage III ALK-Positive NSCLC
The phase II ALNEO trial achieved its primary endpoint, demonstrating a 46% major pathological response rate with neoadjuvant alectinib in 33 patients with potentially resectable stage III ALK-positive NSCLC.
NeoCOAST-2 Trial Shows Promise for Novel Pre-Surgical Combinations in Resectable NSCLC
The Phase II NeoCOAST-2 trial evaluated three novel pre-surgical treatment combinations for resectable non-small cell lung cancer, with the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) arm achieving the highest pathological complete response rate at 35.2%.
Patient-Caregiver Preferences Study Reveals Key Treatment Decision Factors in ALK+ NSCLC
A discrete choice experiment with 205 ALK+ NSCLC patients and 125 caregivers found that both groups overwhelmingly prioritized 3-year progression-free survival when making treatment decisions.
Nuvalent to Present First Clinical Data for Next-Generation ALK Inhibitor NVL-655 at AACR-NCI-EORTC Symposium
Nuvalent will present preliminary dose-escalation data from the ALKOVE-1 Phase 1/2 trial of NVL-655, marking the first clinical disclosure for this next-generation ALK inhibitor.
ROSALINE Trial: Neoadjuvant Letrozole/Entrectinib Shows Limited Efficacy in Invasive Lobular Breast Cancer
The phase 2 ROSALINE trial found that combining entrectinib with letrozole failed to meet its primary endpoint, with no efficacy-evaluable patients achieving residual cancer burden (RCB) of 0 or 1 in invasive lobular breast cancer.
Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC
The ALEK-B phase 2 trial demonstrated that combining alectinib with bevacizumab significantly improved progression-free survival in ALK-positive NSCLC patients, with 97% remaining progression-free at 12 months and 64% at 36 months.
Neoadjuvant Immunotherapy Emerges as Promising Strategy for Early-Stage NSCLC Treatment
Neoadjuvant immune checkpoint inhibitor (ICI) therapy is showing significant promise for locally advanced, resectable non-small cell lung cancer, with patient selection guided by PD-L1 expression, tumor mutational burden, and overall health status.
Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC
Lorlatinib demonstrated a 60% progression-free survival rate at 5 years in patients with ALK-positive advanced non-small cell lung cancer, according to data from the phase 3 CROWN study presented at ASCO 2024.
Nuvalent Advances Toward First NDA Submission with Pivotal Data Expected for ROS1 and ALK Inhibitors in 2025
Nuvalent is preparing to submit its first New Drug Application by mid-2025 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, with pivotal data expected in the first half of 2025.
CHOP Researchers Propose ALK Inhibitors as New Standard for Hereditary Neuroblastoma
A groundbreaking case report from Children's Hospital of Philadelphia demonstrates successful long-term remission in hereditary neuroblastoma patients using targeted ALK inhibitors, potentially transforming treatment protocols.